fortress
biotech
announces
oral
poster
data
presentations
american
society
hematology
ash
annual
meeting
new
york
globe
newswire
fortress
biotech
nasdaq
fbio
fortress
innovative
company
focused
acquiring
developing
commercializing
monetizing
promising
biopharmaceutical
products
product
candidates
today
announced
data
two
clinical
programs
accepted
presentation
american
society
hematology
ash
annual
meeting
held
virtually
december
phase
data
caelum
biosciences
caelum
treatment
relapsed
refractory
amyloid
light
chain
al
amyloidosis
presented
cleveland
clinic
oral
poster
sessions
developed
collaboration
caelum
company
founded
fortress
alexion
pharmaceuticals
recently
progressed
phase
development
addition
interim
phase
data
mustang
bio
mustang
autologous
chimeric
antigen
receptor
car
cell
therapy
patients
relapsed
refractory
lymphomas
presented
mustang
research
partner
fred
hutchinson
cancer
research
center
fred
hutch
poster
session
lindsay
rosenwald
fortress
chairman
president
chief
executive
officer
said
looking
forward
data
two
clinical
programs
presented
oral
poster
sessions
ash
annual
meeting
important
product
candidates
poised
fill
urgent
need
new
treatment
options
make
meaningful
difference
details
presentations
follows
oral
presentation
title
safety
tolerability
efficacy
al
amyloidosis
patients
treated
phase
dose
selection
study
evaluate
safety
tolerability
patients
al
amyloidosis
session
myeloma
amyloidosis
therapy
excluding
transplantation
novel
approaches
relapsed
refractory
myeloma
amyloidosis
abstract
date
time
monday
december
et
presenter
jason
valent
clinical
assistant
professor
medicine
cleveland
clinic
lerner
college
medicine
case
western
reserve
university
staff
department
hematology
oncology
director
multiple
myeloma
program
taussig
cancer
institute
amyloidosis
center
cleveland
clinic
poster
presentation
title
al
amyloidosis
patients
receiving
concomitant
cybord
phase
study
session
myeloma
therapy
excluding
transplantation
poster
ii
abstract
date
time
sunday
december
et
presenter
jason
valent
clinical
assistant
professor
medicine
cleveland
clinic
lerner
college
medicine
case
western
reserve
university
staff
department
hematology
oncology
director
multiple
myeloma
program
taussig
cancer
institute
amyloidosis
center
cleveland
clinic
poster
presentation
title
third
generation
targeted
car
therapy
treatment
patients
relapsed
refractory
lymphoma
session
immunotherapies
poster
abstract
date
time
saturday
december
et
presenter
mazyar
shadman
associate
professor
clinical
research
division
fred
hutch
seattle
wa
information
please
visit
ash
annual
meeting
exposition
website
https
meetings
abstracts
light
chain
monoclonal
antibody
al
amyloidosis
monoclonal
antibody
mab
designed
improve
organ
function
reducing
eliminating
amyloid
deposits
tissues
organs
patients
al
amyloidosis
antibody
designed
bind
misfolded
light
chain
protein
amyloid
shows
binding
kappa
lambda
subtypes
phase
study
demonstrated
improved
organ
function
including
cardiac
renal
function
patients
relapsed
refractory
al
amyloidosis
previously
organ
response
standard
care
therapy
received
orphan
drug
designation
food
drug
administration
european
medicine
agency
therapy
patients
al
amyloidosis
caelum
biosciences
caelum
biosciences
caelum
biotechnology
company
developing
treatments
rare
diseases
caelum
lead
asset
novel
antibody
treatment
patients
amyloid
light
chain
al
amyloidosis
caelum
entered
collaboration
agreement
alexion
alexion
acquired
minority
equity
interest
caelum
exclusive
option
acquire
remaining
equity
company
based
phase
data
caelum
founded
fortress
biotech
nasdaq
fbio
information
visit
car
cell
therapy
surface
molecule
plays
role
differentiation
plasma
cells
car
developed
mustang
research
partner
fred
hutchinson
cancer
research
center
fred
hutch
laboratory
oliver
press
brian
till
clinical
research
division
exclusively
licensed
mustang
bio
optimized
car
derived
fully
human
antibody
currently
phase
trial
fred
hutch
lymphoma
patients
additional
information
trial
found
http
using
identifier
mustang
bio
mustang
bio
biopharmaceutical
company
focused
translating
today
medical
breakthroughs
cell
gene
therapies
potential
cures
hematologic
cancers
solid
tumors
rare
genetic
diseases
mustang
aims
acquire
rights
technologies
licensing
otherwise
acquiring
ownership
interest
fund
research
development
outlicense
bring
technologies
market
mustang
partnered
top
medical
institutions
advance
development
car
therapies
across
multiple
cancers
well
lentiviral
gene
therapy
severe
combined
immunodeficiency
xscid
also
known
bubble
boy
disease
mustang
registered
securities
exchange
act
amended
files
periodic
reports
securities
exchange
commission
sec
mustang
founded
fortress
biotech
nasdaq
fbio
information
visit
fortress
biotech
fortress
biotech
fortress
innovative
biopharmaceutical
company
ranked
number
deloitte
technology
fast
annual
ranking
north
american
companies
technology
media
telecommunications
life
sciences
energy
tech
sectors
based
percentage
fiscal
year
revenue
growth
period
fortress
focused
acquiring
developing
commercializing
marketed
drugs
drug
candidates
company
five
marketed
prescription
pharmaceutical
products
programs
development
fortress
partners
partners
founded
holds
significant
minority
ownership
positions
product
candidates
span
six
areas
including
oncology
rare
diseases
gene
therapy
allow
create
value
shareholders
fortress
advances
diversified
pipeline
streamlined
operating
structure
fosters
efficient
drug
development
fortress
model
driven
business
development
team
focused
leveraging
significant
biopharmaceutical
industry
expertise
expand
company
portfolio
product
opportunities
fortress
established
partnerships
world
leading
academic
research
institutions
biopharmaceutical
companies
maximize
opportunity
full
potential
including
alexion
pharmaceuticals
astrazeneca
city
hope
fred
hutchinson
cancer
research
center
invagen
pharmaceuticals
subsidiary
cipla
limited
jude
children
research
hospital
nationwide
children
hospital
information
visit
statements
press
release
may
contain
statements
within
meaning
section
securities
act
section
securities
exchange
act
amended
used
throughout
press
release
words
us
may
refer
fortress
individually
together
one
partner
companies
dictated
context
statements
include
limited
statements
relating
growth
strategy
product
development
programs
statements
historical
facts
statements
based
management
current
expectations
subject
risks
uncertainties
could
negatively
affect
business
operating
results
financial
condition
stock
price
factors
could
cause
actual
results
differ
materially
currently
anticipated
include
risks
relating
growth
strategy
ability
obtain
perform
maintain
financing
strategic
agreements
relationships
risks
relating
results
research
development
activities
uncertainties
relating
preclinical
clinical
testing
risks
relating
timing
starting
completing
clinical
trials
dependence
suppliers
risks
relating
outbreak
potential
impact
employees
consultants
ability
complete
work
timely
manner
ability
obtain
additional
financing
favorable
terms
ability
attract
integrate
retain
key
personnel
early
stage
products
development
need
substantial
additional
funds
government
regulation
patent
intellectual
property
matters
competition
well
risks
described
sec
filings
expressly
disclaim
obligation
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
expectations
changes
events
conditions
circumstances
statement
based
except
may
required
law
claim
protection
safe
harbor
statements
contained
private
securities
litigation
reform
act
information
contained
herein
intended
reviewed
totality
stipulations
conditions
provisos
apply
given
piece
information
one
part
press
release
read
applying
mutatis
mutandis
every
instance
information
appearing
herein
company
contacts
jaclyn
jaffe
william
begien
fortress
biotech
ir
investor
relations
contact
daniel
ferry
lifesci
advisors
llc
daniel
